Literature DB >> 19451745

Effect of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on telomerase activity in pancreatic cancer-derived cell lines.

Alpana Kumari1, Radhika Srinivasan, Jai Dev Wig.   

Abstract

BACKGROUND: The gene promoter region of human telomerase reverse transcriptase (hTERT) contains binding sites for c-myc and E2F1 as well as CpG islands, suggesting regulation by genetic factors and epigenetically by methylation. Hence, the effect of the demethylating agent 5-azacytidine and silencing of c-MYC and E2F1 genes on its expression and consequently on telomerase activity were studied in pancreatic cancer-derived cell lines.
METHODS: MIaPaCa-2 and PANC-1 cell lines were transfected with SiRNA against E2F1 and c-MYC genes separately as well as along with 5-azacytidine treatment. The hTERT gene methylation status was determined by methylation-specific PCR and telomerase activity quantitated by TRAP-PCR-ELISA.
RESULTS: Demethylation by 5-azacytidine resulted in hTERT inhibition with a reduction in telomerase activity to 37-49% of controls. Silencing of E2F-1 or c-MYC also decreased the hTERT transcript and telomerase activity with a more pronounced effect with respect to c-MYC silencing. There was a synergistic effect of demethylation and gene silencing on the inhibition of hTERT mRNA expression which resulted in undetectable levels of telomerase activity.
CONCLUSION: Telomerase activity, which is necessary for cellular immortalization, can be shut down by a combined approach using SiRNA-mediated gene silencing and demethylating agents, which has therapeutic implications. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451745     DOI: 10.1159/000212094

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  7 in total

Review 1.  Genetic and epigenetic trends in telomere research: a novel way in immunoepigenetics.

Authors:  Dora Melicher; Edit I Buzas; Andras Falus
Journal:  Cell Mol Life Sci       Date:  2015-07-20       Impact factor: 9.261

2.  Identification of Spindle and Kinetochore-Associated Family Genes as Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment.

Authors:  Yi Liu; Zong-Rui Jin; Xing Huang; Ye-Cheng Che; Qin Liu
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

3.  Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors.

Authors:  Jean-Pierre Issa; Ignacio I Wistuba; Razelle Kurzrock; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta
Journal:  Clin Epigenetics       Date:  2014-01-09       Impact factor: 6.551

4.  Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy.

Authors:  Xing Wang; Jiandi Yu; Junfeng Yan; Kun Peng; Haiyong Zhou
Journal:  BMC Urol       Date:  2022-03-19       Impact factor: 2.264

5.  Methylated Host Cell Gene Promoters and Human Papillomavirus Type 16 and 18 Predicting Cervical Lesions and Cancer.

Authors:  Nina Milutin Gašperov; Ivan Sabol; Pavao Planinić; Goran Grubišić; Ivan Fistonić; Ante Ćorušić; Magdalena Grce
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

6.  Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).

Authors:  Xinbing Sui; Na Kong; Zhanggui Wang; Hongming Pan
Journal:  Oncol Lett       Date:  2013-05-29       Impact factor: 2.967

7.  Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription.

Authors:  Songsong Liu; Yao Zheng; Yujun Zhang; Junfeng Zhang; Fuming Xie; Shixiang Guo; Jianyou Gu; Jiali Yang; Ping Zheng; Jiejuan Lai; Liangyu Yin; Huaizhi Wang
Journal:  Theranostics       Date:  2020-08-25       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.